High-flow Nasal Oxygen Therapy for Advanced Endoscopy in High-risk Patients.
Completed · Not applicable · NCT06610461
Conditions: Hypoxemia During Surgery
At a glance
- Research payments reported, 2025
- $45,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 180
About the trial
- Sponsor
- Beth Israel Deaconess Medical Center
- Tested
- HFNO-Treatment (device)
- Dates
- Started 2024-09-25; completion 2025-09-12
- Results posted
- Not yet
Anesthesia is crucial during upper GI endoscopy in order to improve the procedural conditions for the interventionist, increase the quality of examination and alleviate patient discomfort. However, sedation during endoscopy carries a serious risk of blood oxygen desaturation. This study aims to investigate the hypothesis if the application of high-flow nasal oxygen (HFNO) during high-risk gastroscopy reduces the risk of blood oxygen levels to drop below a defined threshold. Enrolled patients will be randomly assigned to either the control group, receiving standard care during endoscopy, or the intervention group, receiving HFNO therapy during the procedure. Throughout the intervention, vi…
From ClinicalTrials.gov, last updated 2025-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Fisher & Paykel Healthcare Limited reported $45,500 in research payments for this study in 2025 (1 payments).
Products named: Fisher & PAykel Healthcare
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.